scholarly journals Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene

2018 ◽  
Vol 44 (1) ◽  
Author(s):  
Alice Maguolo ◽  
Franco Antoniazzi ◽  
Alice Spano ◽  
Elena Fiorini ◽  
Rossella Gaudino ◽  
...  
Author(s):  
Robin D. Clark ◽  
Cynthia J. Curry

This chapter reviews information on disorders that cause large birth weight, macrosomia, and/or segmental overgrowth. The most common of these conditions is seen in infants of diabetic mothers. Abnormal dosage of growth regulating genes make chromosomal microarray abnormalities a relatively common cause of overgrowth. Particularly notable is the distinctive Pallister Killian syndrome (12p tetrasomy). Other common overgrowth syndromes include Beckwith-Wiedemann syndrome, Sotos, Malan, and Weaver syndromes. The RASopathy syndromes including Noonan syndrome* and Costello syndrome are also often large at birth. Segmental overgrowth syndromes including Proteus and Klippel Trenaunay as well as PIK3CA related overgrowth (PROS) are discussed as well as their somatic mosaic origin in affected tissues. Clinical guidelines for evaluation and surveillance are outlined. The clinical case presentation features an infant with Sotos syndrome.


2019 ◽  
pp. 199-216 ◽  
Author(s):  
Leslie G. Biesecker

Proteus syndrome is an exceedingly rare disorder, perhaps the least common of all overgrowth syndromes but one of the most distinctive because of its segmental nature and unrelenting progression. Proteus syndrome occurs sporadically and was the first of the segmental overgrowth syndromes found to be caused by somatic mosaicism. The discovery of an activating mutation in AKT1 by Les Biesecker and colleagues at the National Institutes of Health provided the initial molecular proof for somatic mosaicism in Proteus syndrome. Overgrowth in Proteus syndrome can involve nearly any tissue or part of the body. Presumably a germline mutation that would affect all tissues of the body would be lethal. Overgrowth of a tissue or a body part is the distinctive manifestation of Proteus syndrome but in most cases will be accompanied by other cutaneous, skeletal, vascular, or soft tissue findings. Although the possibility of an increased risk for developing neoplastic disease is a concern in any overgrowth disorder, this has not been demonstrated in Proteus syndrome.


This book provides comprehensive details on a number of well-defined genetic disorders and a selection of less well-defined entities that include somatic overgrowth as a major manifestation. In addition to overgrowth, these syndromes each have their own distinguishing characteristics that benefit the clinician in making a specific diagnosis. In most cases, the causative genes are known, giving a means of laboratory confirmation of the diagnoses. A major distinction from other hereditary syndromes is a predisposition of patients with the overgrowth syndromes to develop neoplasms during childhood. In some cases, the overgrowth seems to be limited, even to the extent that some growth parameters may return to the normal range by adulthood. In other cases, the overgrowth is notable throughout life. In recent years, both the generalized and the segmental overgrowth syndromes have begun to yield their secrets to molecular technologies. These studies have provided clinicians a way to confirm the specific diagnosis so they can provide appropriate counseling and anticipatory management. In the case of segmental overgrowth disorders, they have also established their mosaic nature, which explains the sporadic occurrence and marked phenotype variability.


2015 ◽  
Vol 135 (5) ◽  
pp. 1450-1453 ◽  
Author(s):  
Leila Youssefian ◽  
Hassan Vahidnezhad ◽  
Taghi Baghdadi ◽  
Alireza Ghaznavi ◽  
Qiaoli Li ◽  
...  

FACE ◽  
2021 ◽  
pp. 273250162110482
Author(s):  
Rishub K. Das ◽  
Barry G. Rahman ◽  
James D. Phillips ◽  
Alexandra J. Borst ◽  
Nolan Jaeger ◽  
...  

Overgrowth syndromes encompass a number of rare genetic diseases with heterogeneous clinical phenotypes. Accordingly, there is a strong imperative to collect data and classify these disorders to aid in diagnosis and management. Recent advances in the genetics of overgrowth syndromes have identified mutations in the PIK3CA gene. These somatic mutations manifest in progressive segmental overgrowth of fibrous and adipose tissue and bone, vascular malformations, and in some cases, increased risk for malignancy. Targeted medical therapy is under investigation for the management of PROS, but treatment of overgrowth relies on surgical debulking. Macrotia in PIK3CA-related overgrowth spectrum (PROS) has not been reported in the literature. In this case, we discuss a novel approach to reductive otoplasty and facial soft tissue debulking in a pediatric patient with PROS.


2020 ◽  
Author(s):  
A Laufer ◽  
A Frommer ◽  
G Gosheger ◽  
R Rödl ◽  
AM Rachbauer ◽  
...  

2021 ◽  
pp. 195-201
Author(s):  
Emily Sideris ◽  
Er Tsing Vivian Tng ◽  
Paul Chee

We present a rare case of KRAS keratinocytic epidermal nevus syndrome with lymphatic malformation, responsive to treatment with sirolimus, an mTOR inhibitor. A brief review of the current literature regarding sirolimus use in vascular malformations, lymphatic malformations, regional overgrowth syndromes, and RASopathies is discussed.


Sign in / Sign up

Export Citation Format

Share Document